Study of the effect of myrtus communis L.extract on Alzheimer's disease

Investigation of physicochemical properties and clinical effects of Capsule containing standardized hydroalcoholic extract of myrtus communis L. leaves in the treatment of mild to moderate Alzheimer's disease (AD): A randomized double-blind placebo controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170702034861N8

Enrollment

Registered

2019-08-26

Start date

2018-11-22

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease. Other degenerative diseases of the nervous system

Interventions

Intervention 1: Intervention group: A 500 mg capsule containing an extract of myrtus communis, which was made by Pharmacognosist at the Kerman Pharmaceutical Faculty, was received every 8 hours for fo

Eligibility

Sex/Gender

All

Age

50 Years to 85 Years

Inclusion criteria

Inclusion criteria: Age 50 to 85 years MMSE score between 16 and 24 No drug abuse and alcohol dependence Not taking anticoagulants Ability to answer questions and no mental problems

Exclusion criteria

Exclusion criteria: depression

Design outcomes

Primary

Measure	Time frame
• Cognitive status of patients. Timepoint: Before and after 4 weeks of intervention. Method of measurement: Mini-Mental State Exam (MMSE) and Clinical Dementia Rating (CDR)questionnair.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactPegah Nooraee

Kerman University of Medical Sciences

pegahn73p@gmail.com+98 34 3132 5600

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026